Line 10: |
Line 10: |
| * Quantification of Hgb mass loss vs. qBL in C-section. | | * Quantification of Hgb mass loss vs. qBL in C-section. |
| | | |
− | ==Not Super Exciting== | + | ==Very Ambitious, But Still Cool== |
− | * Which findings on the preop note predict pressors use during the case? | + | * NIBP monitoring from head/neck |
− | * EPIC timeline builder | + | * Better way of determining fluid status |
− | * Ultrasound vs blind A-line first attempt success rate and complications? | + | * Novel reversal agents (e.g. volatile anesthetics, propofol, precedex) |
| + | * Reversible chemical/optical/electromagnetic knockdown/inhibition/interference of pain nuclei/DRG/dorsal column/STT activity in rodents/primates |
| | | |
| ==Already Done== | | ==Already Done== |
Line 20: |
Line 21: |
| * Does precedex really delay emergence? ([https://journals.lww.com/anesthesia-analgesia/fulltext/2022/06000/the_effect_of_dexmedetomidine_on_postanesthesia.17.aspx 2022 Anesthesia and Analgesia Systematic Review and Meta-Analysis] says "NO"). | | * Does precedex really delay emergence? ([https://journals.lww.com/anesthesia-analgesia/fulltext/2022/06000/the_effect_of_dexmedetomidine_on_postanesthesia.17.aspx 2022 Anesthesia and Analgesia Systematic Review and Meta-Analysis] says "NO"). |
| | | |
− | ==Very Ambitious, But Still Cool== | + | ==Not Super Exciting/Impactful== |
− | * NIBP monitoring from head/neck | + | * Which findings on the preop note predict pressors use during the case? |
− | * Better way of determining fluid status
| + | * EPIC timeline builder |
− | * Novel reversal agents (e.g. volatile anesthetics, propofol, precedex) | + | * Ultrasound vs blind A-line first attempt success rate and complications? |
− | * Reversible chemical/optical/electromagnetic knockdown/inhibition/interference of pain nuclei/DRG/dorsal column/STT activity in rodents/primates | |
| | | |
| =Resources= | | =Resources= |